Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis.

Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2024)

Proprotein convertase subtilisin kexin type 9 inhibitor incomplete dosing-related complications are frequently reported in the postmarketing setting. Systematic efforts to understand the incidence and mechanisms of dosing failure and associated patient burdens are needed.

Keyphrases

risk factors
low density lipoprotein
case report
quality improvement
adverse drug